0001062993-24-010536.txt : 20240516
0001062993-24-010536.hdr.sgml : 20240516
20240516192035
ACCESSION NUMBER: 0001062993-24-010536
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240514
FILED AS OF DATE: 20240516
DATE AS OF CHANGE: 20240516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOHLIN GAREN G
CENTRAL INDEX KEY: 0001254705
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 24957326
MAIL ADDRESS:
STREET 1: C/O PRAECIS PHARMACEUTICALS INC
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-05-14
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001254705
BOHLIN GAREN G
C/O COLLEGIUM PHARMACEUTICAL, INC.
100 TECHNOLOGY CENTER DRIVE
STOUGHTON
MA
02072
1
0
0
0
0
Common Stock
2024-05-14
4
M
0
28985
5.73
A
73760
D
Common Stock
2024-05-14
4
S
0
28985
32.3033
D
44775
D
Common Stock
2024-05-16
4
A
0
7693
0.00
A
52468
D
Stock Option (Right to Purchase)
5.73
2024-05-14
4
M
0
28985
0
D
2025-03-19
Common Stock
28985
0
D
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
The option is fully vested and exercisable.
/s/ Shirley R. Kuhlmann as Attorney-in-Fact for Garen G. Bohlin
2024-05-16